CSIMarket
 
Corbus Pharmaceuticals Holdings Inc   (CRBP)
Other Ticker:  
 
 
Price: $39.2400 $3.09 8.548%
Day's High: $40 Week Perf: 2.86 %
Day's Low: $ 35.16 30 Day Perf: 50.52 %
Volume (M): 235 52 Wk High: $ 49.87
Volume (M$): $ 9,225 52 Wk Avg: $11.27
Open: $35.42 52 Wk Low: $3.03



 Market Capitalization (Millions $) 174
 Shares Outstanding (Millions) 4
 Employees 57
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -47
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings Inc. is a clinical-stage biopharmaceutical company that is focused on discovering, developing, and commercializing innovative therapies to address serious and unmet medical needs in the areas of inflammation and fibrosis. The company is headquartered in Norwood, Massachusetts, and was founded in 2009.

Corbus Pharmaceuticalse lead product candidate is lenabasum, which is a first-in-class, oral, small molecule drug that acts as a selective cannabinoid receptor type 2 (CB2) agonist. Lenabasum has been designed to target and activate CB2 receptors on immune cells, resolving chronic inflammation and fibrosis without impairing normal immune function.

The company has several clinical trials underway for lenabasum, including a phase 3 study in systemic sclerosis, a phase 2b study in dermatomyositis, and a phase 2 study in cystic fibrosis. In addition to these trials, Corbus is also exploring the potential for lenabasum in other indications, such as lupus, systemic lupus erythematosus, and COVID-19.

Beyond lenabasum, Corbus Pharmaceuticals has a pipeline of drug candidates in various stages of development. This includes CRB-4001, a cannabinoid receptor type 1 (CB1) inverse agonist that is in preclinical development for the treatment of nonalcoholic steatohepatitis (NASH), and CRB-5003, a peripherally restricted CB1 inverse agonist that is being developed for the treatment of chronic pain and other indications.

Corbus Pharmaceuticals has a strong focus on patient advocacy and building relationships with patient communities. The company has established partnerships with patient organizations to raise awareness about the diseases it is targeting and to provide educational resources to patients and caregivers.

Corbus Pharmaceuticals is led by a team of experienced industry professionals, including Chief Executive Officer Yuval Cohen, who has more than 30 years of experience in the biopharmaceutical industry, and Chief Medical Officer Barbara White, who has extensive experience in clinical development and regulatory affairs. The company has also assembled a world-class scientific advisory board that includes leading experts in the fields of inflammation and fibrosis.

Overall, Corbus Pharmaceuticals is a company that is dedicated to developing innovative therapies that can make a significant difference in the lives of patients suffering from serious and debilitating diseases. The companyes focus on patient advocacy and strong leadership team positions it well for long-term success in the biopharmaceutical industry.


   Company Address: 500 River Ridge Drive Norwood 2062 MA
   Company Phone Number: 963-0100   Stock Exchange / Ticker: NASDAQ CRBP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Corbus Pharmaceuticals Announces Successful Public Offering, Elevating Shareholders' Confidence

Published Wed, Jan 31 2024 2:20 PM UTC



NORWOOD, Mass., Jan. 31, 2024 - Corbus Pharmaceuticals Holdings Inc. has proven its prowess in the precision oncology industry once again with the successful pricing of its underwritten public offering. The company, listed on the Nasdaq under the ticker symbol CRBP, unveiled the pricing of 4,325,000 shares of its common stock at a public offering price of $19.00 pe...

Clinical Study

CRB-701 (SYS6002): A Beacon of Hope in Nectin-4 Positive Tumor Treatment

Published Fri, Jan 26 2024 12:30 PM UTC

Corbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results from the first-in-human clinical study of their investigational drug, CRB-701 (SYS6002), presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The ongoing Phase 1 dose escalation study is being conducted in China and focuses on...

Clinical Study

Phase 1 Dose Escalation Study of SYS6002 (CRB-701): Latest Clinical Data to be Presented at 2024 ASCO GU Symposium

Published Tue, Jan 23 2024 1:01 PM UTC

Corbus Pharmaceuticals Holdings, Inc., a progressive biopharmaceutical company, announced the release of the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (also known as CRB-701). The abstract will serve as the basis for the upcoming presentation, intended to launch at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (...

Product Service News

CRB-601: A Potential Breakthrough in Targeted Cancer Therapy via Tumor Immune Exclusion Overcoming and Immune Checkpoint Inhibition Enhancement

Published Tue, Jan 9 2024 1:00 PM UTC

In the field of cancer therapeutics, precision oncology approaches have gained significant attention due to their promise in delivering personalized treatments with improved efficacy. Corbus Pharmaceuticals Holdings, Inc. has achieved a major milestone with the clearance of the investigational new drug application of CRB-601 by the U.S. Food and Drug Administration (FDA). CR...

Product Service News

Unleashing Precision Oncology: Corbus Pharmaceuticals' Groundbreaking ADC to be Presented at ASCO GU Symposium

Published Mon, Dec 18 2023 1:00 PM UTC



NORWOOD, Mass., Dec. 18, 2023 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently made a significant announcement that holds tremendous potential for advancing precision oncology. The company disclosed that the Phase 1 clinical data from a dose escalation study of CRB-701 (SYS6002), a next-generation antibody-drug conjugate (ADC), has been accepted ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com